CT-P13, an infliximab biosimilar, achieved statistically similar improvements in disease activity disability, and mobility in patients with ankylosing spondylitis (AS) compared to infliximab (INX), results from the PLANETAS study found at the European League Against Rheumatism Annual Congress (EULAR 2014).

In the PLANETAS study (n=250), clinical disease activity was measured by ASAS20/40 and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), disability measured by the Bath Ankylosing Spondylitis Functional Index (BASFI), and mobility measured by the Bath Ankylosing Spondylitis Metrology Index (BASMI).

RELATED: Spinal Fx Complications, Mortality Up With Ankylosing Spondylitis

At Week 54, BASDAI improved significantly from baseline in both treatment groups (CT-P13 from 6.74 to 3.78; INX from 6.57 to 3.70) and this improvement was similar between groups (-0.29; 95% CI -0.91 to 0.32).

Improvements in BASFI and BASMI were also similar: BASFI (CT-P13 from 6.20 to 3.42; INX from 6.24 to 3.46) and BASMI (CT-P13 from 4.0 to 2.8; INX from 4.1 to 3.2). Further, a 50% improvement of the baseline BASDAI (BASDAI50) was achieved in 44.3% for CT-P13 treated patients and 46.3% for INX treated patients at Week 54. The BASDAI50 response rate was comparable between the two groups (P=0.7737).

For more information visit EULAR.org.